Hematologic Malignancies

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

By

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

By

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

By

In the treatment of myeloma, researchers are using therapies engineered to target a protein on myeloma cells called B cell maturation antigen.

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

By

At the median follow-up 22.9 months, 56.3% of patients in the BV arm achieved a significantly superior objective global response lasting at least 4 months vs 12.5% of patients in the IC arms.

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

By By

Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

By

Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.

Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab

Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab

By

Four-year follow-up data of the ELOQUENT-2 trial demonstrated that elotuzumab plus lenalidomide/dexamethasone has ongoing efficacy among patients with relapsed/refractory multiple myeloma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs